CV Therapeutics Rejects Astellas Bid Again, Reports $37 Million Q4 Loss

CV Therapeutics Inc. said it rejected an unsolicited $1 billion acquisition proposal from Astellas Pharma Inc. for the second time, and reported a widened fourth quarter loss of $37 milion, or 60 cents a share.
Silicon Valley/San Jose Business Journal